Edition:
India

Enlivex Therapeutics Ltd (ENLV.OQ)

ENLV.OQ on NASDAQ Stock Exchange Capital Market

27.90USD
21 Aug 2019
Change (% chg)

$-0.30 (-1.06%)
Prev Close
$28.20
Open
$27.20
Day's High
$27.90
Day's Low
$27.00
Volume
2,035
Avg. Vol
3,739
52-wk High
$29.50
52-wk Low
$6.32

Latest Key Developments (Source: Significant Developments)

Enlivex Therapeutics Says Enrollment Of Last Cohort In Sepsis Study Approved
Monday, 19 Aug 2019 

Aug 19 (Reuters) - Enlivex Therapeutics Ltd ::ENLIVEX THERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM SAFETY COMMITTEE’S REVIEW OF SIX PATIENTS WITH SEVERE SEPSIS PATIENTS; ENROLLMENT OF LAST STUDY COHORT APPROVED.ENLIVEX THERAPEUTICS LTD - FOLLOWING RECOMMENDATION, REGULATORY AUTHORITIES APPROVED CONTINUED ENROLLMENT IN LAST COHORT IN STUDY.ENLIVEX THERAPEUTICS LTD - NO SERIOUS ADVERSE EVENTS ASSOCIATED WITH OTS ALLOCETRA WERE PRESENTED.ENLIVEX THERAPEUTICS LTD - PLANS TO INITIATE A PHASE II CLINICAL STUDY OF OTS ALLOCETRA IN UP TO 40 PATIENTS WITH SEPSIS.ENLIVEX THERAPEUTICS LTD - SIX PATIENTS IN PHASE IB CLINICAL TRIAL OF OTS ALLOCETRA HAD SEVERE SEPSIS AT TIME OF OTS ALLOCETRA INFUSION.ENLIVEX THERAPEUTICS LTD - ALL SIX PATIENTS TOLERATED INFUSION WITHOUT SERIOUS ADVERSE EVENTS, DEMONSTRATED SWIFT CLINICAL IMPROVEMENT.  Full Article

Bioblast Pharma Announces Entry Into Merger Agreement To Acquire Enlivex Therapeutics
Tuesday, 20 Nov 2018 

Nov 19 (Reuters) - Bioblast Pharma Ltd ::BIOBLAST PHARMA LTD. ANNOUNCES ENTRY INTO MERGER AGREEMENT TO ACQUIRE ENLIVEX THERAPEUTICS LTD. TO ADVANCE CLINICAL STAGE IMMUNOTHERAPEUTIC DRUG PIPELINE FOR THE TREATMENT OF LIFE-THREATENING DISEASES SEPSIS, GVHD AND SOLID TUMORS.BIOBLAST PHARMA LTD - TERMS OF TRANSACTION INCLUDE A CONTINGENT VALUE RIGHT (CVR) TO BE DISTRIBUTED TO BIOBLAST SHAREHOLDERS.BIOBLAST PHARMA LTD - OWNERSHIP SPLIT OF COMBINED COMPANY ANTICIPATED TO BE APPROXIMATELY 96% ENLIVEX SHAREHOLDERS AND 4% BIOBLAST SHAREHOLDERS.BIOBLAST PHARMA LTD - COMBINED COMPANY WILL BE RENAMED ENLIVEX THERAPEUTICS LTD., AND ITS TRADING TICKER WILL CHANGE ACCORDINGLY.BIOBLAST PHARMA LTD - "IT IS ANTICIPATED THAT COMBINED COMPANY WILL BE WELL FINANCED AT CLOSING OF TRANSACTION".BIOBLAST PHARMA LTD - EXPECTED THAT SHAI NOVIK, CURRENT EXECUTIVE CHAIRMAN OF ENLIVEX WILL SERVE AS EXECUTIVE CHAIRMAN OF COMBINED COMPANY.BIOBLAST PHARMA LTD - SHMUEL HESS, CURRENT CEO OF ENLIVEX, WILL SERVE AS CEO OF COMBINED COMPANY.  Full Article

Bioblast Pharma Says Effective July 31, Chairman & CEO Will Step Down
Friday, 27 Jul 2018 

July 26 (Reuters) - Bioblast Pharma Ltd ::BIOBLAST PHARMA - DETERMINED IT IS IN BEST INTEREST OF CO'S SHAREHOLDERS TO FURTHER REDUCE EXPENSES.BIOBLAST PHARMA LTD - EFFECTIVE JULY 31, FREDRIC PRICE WILL BE STEPPING DOWN AS CHAIRMAN & CEO.BIOBLAST PHARMA - FREDRIC PRICE WILL BE LEAVING BOARD, ALONG WITH 4 INDEPENDENT MEMBERS OF BOARD.BIOBLAST PHARMA LTD - WARREN WASIEWSKI, STEPPED DOWN AS COMPANY'S CHIEF MEDICAL OFFICER.BIOBLAST PHARMA LTD - DALIA MEGIDDO, COMPANY CO-FOUNDER, WILL REMAIN ON BOARD AND WILL SERVE AS CEO AND CMO.BIOBLAST PHARMA - WORKING DILIGENTLY TO FIND COMMERCIAL PARTNER FOR INVESTIGATIONAL PROPRIETARY INTRAVENOUS FORM OF TREHALOSE 90 MG/ML SOLUTION.BIOBLAST PHARMA LTD - WORKING DILIGENTLY TO ENTER INTO A MERGER AGREEMENT WITH A THIRD PARTY.  Full Article

Bioblast Pharma reports Q3 loss per share $0.32
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Bioblast Pharma Ltd :Bioblast Pharma reports third quarter 2017 financial results.Q3 loss per share $0.32.  Full Article